Candel TherapeuticsCADL
Market Cap: $197M
About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees: 42
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
519% more capital invested
Capital invested by funds: $5.97M [Q1] → $37M (+$31M) [Q2]
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
125% more funds holding
Funds holding: 20 [Q1] → 45 (+25) [Q2]
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
6.96% more ownership
Funds ownership: 13.07% [Q1] → 20.03% (+6.96%) [Q2]
10% less call options, than puts
Call options by funds: $548K | Put options by funds: $612K
Research analyst outlook
We haven’t received any recent analyst ratings for CADL.